Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Human rDNA and Cancer

E. Smirnov, N. Chmúrčiaková, D. Cmarko

. 2021 ; 10 (12) : . [pub] 20211208

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Grant support
Charles University (Progres Q28) and the Grant Agency of Czech Republic (19-21715S) Grant Agency of Czech Republic and Charles university

In human cells, each rDNA unit consists of the ~13 kb long ribosomal part and ~30 kb long intergenic spacer (IGS). The ribosomal part, transcribed by RNA polymerase I (pol I), includes genes coding for 18S, 5.8S, and 28S RNAs of the ribosomal particles, as well as their four transcribed spacers. Being highly repetitive, intensively transcribed, and abundantly methylated, rDNA is a very fragile site of the genome, with high risk of instability leading to cancer. Multiple small mutations, considerable expansion or contraction of the rDNA locus, and abnormally enhanced pol I transcription are usual symptoms of transformation. Recently it was found that both IGS and the ribosomal part of the locus contain many functional/potentially functional regions producing non-coding RNAs, which participate in the pol I activity regulation, stress reactions, and development of the malignant phenotype. Thus, there are solid reasons to believe that rDNA locus plays crucial role in carcinogenesis. In this review we discuss the data concerning the human rDNA and its closely associated factors as both targets and drivers of the pathways essential for carcinogenesis. We also examine whether variability in the structure of the locus may be blamed for the malignant transformation. Additionally, we consider the prospects of therapy focused on the activity of rDNA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011728
003      
CZ-PrNML
005      
20220506131444.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cells10123452 $2 doi
035    __
$a (PubMed)34943960
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Smirnov, Evgeny $u Laboratory of Cell Biology, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 01 Prague, Czech Republic
245    10
$a Human rDNA and Cancer / $c E. Smirnov, N. Chmúrčiaková, D. Cmarko
520    9_
$a In human cells, each rDNA unit consists of the ~13 kb long ribosomal part and ~30 kb long intergenic spacer (IGS). The ribosomal part, transcribed by RNA polymerase I (pol I), includes genes coding for 18S, 5.8S, and 28S RNAs of the ribosomal particles, as well as their four transcribed spacers. Being highly repetitive, intensively transcribed, and abundantly methylated, rDNA is a very fragile site of the genome, with high risk of instability leading to cancer. Multiple small mutations, considerable expansion or contraction of the rDNA locus, and abnormally enhanced pol I transcription are usual symptoms of transformation. Recently it was found that both IGS and the ribosomal part of the locus contain many functional/potentially functional regions producing non-coding RNAs, which participate in the pol I activity regulation, stress reactions, and development of the malignant phenotype. Thus, there are solid reasons to believe that rDNA locus plays crucial role in carcinogenesis. In this review we discuss the data concerning the human rDNA and its closely associated factors as both targets and drivers of the pathways essential for carcinogenesis. We also examine whether variability in the structure of the locus may be blamed for the malignant transformation. Additionally, we consider the prospects of therapy focused on the activity of rDNA.
650    _2
$a intergenová DNA $x genetika $7 D021901
650    _2
$a ribozomální DNA $x genetika $7 D004275
650    _2
$a genetická variace $x genetika $7 D014644
650    _2
$a lidé $7 D006801
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a nádory $x genetika $x patologie $7 D009369
650    _2
$a nekódující RNA $x genetika $7 D022661
650    _2
$a ribozomy $x genetika $7 D012270
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Chmúrčiaková, Nikola $u Laboratory of Cell Biology, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 01 Prague, Czech Republic $1 https://orcid.org/0000000340807557
700    1_
$a Cmarko, Dušan $u Laboratory of Cell Biology, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 01 Prague, Czech Republic $1 https://orcid.org/0000000274678565
773    0_
$w MED00194911 $t Cells $x 2073-4409 $g Roč. 10, č. 12 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34943960 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131436 $b ABA008
999    __
$a ok $b bmc $g 1789361 $s 1162926
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 10 $c 12 $e 20211208 $i 2073-4409 $m Cells $n Cells $x MED00194911
GRA    __
$a Charles University (Progres Q28) and the Grant Agency of Czech Republic (19-21715S) $p Grant Agency of Czech Republic and Charles university
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...